Nicola Longo

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4156482/nicola-longo-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136 papers	4,094 citations	33 h-index	59 g-index
152 ext. papers	4,913 ext. citations	4.6 avg, IF	5.5 L-index

#	Paper	IF	Citations
136	Biomarkers for Drug Development in Propionic and Methylmalonic Acidemias.. *Journal of Inherited Metabolic Disease*, **2022**,	5.4	1
135	Timing of therapy and neurodevelopmental outcomes in 18 families with pyridoxine-dependent epilepsy.. *Molecular Genetics and Metabolism*, **2022**, 135, 350-356	3.7	2
134	Gene Therapy for Inherited Metabolic Diseases **2022**, 97-109		
133	Medical and Nutrition Management of Phenylketonuria: Pegvaliase **2022**, 153-167		
132	A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials. *Molecular Genetics and Metabolism Reports*, **2021**, 29, 100810	1.8	0
131	Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. *Clinical and Translational Science*, **2021**, 14, 1894-1905	4.9	0
130	Phenylketonuria. *Nature Reviews Disease Primers*, **2021**, 7, 36	51.1	15
129	Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency. *Molecular Genetics and Metabolism*, **2021**, 134, 60-64	3.7	1
128	Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. *Journal of Inherited Metabolic Disease*, **2021**, 44, 178-192	5.4	15
127	Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. *Journal of Inherited Metabolic Disease*, **2021**, 44, 253-263	5.4	11
126	Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study. *Clinical Nutrition ESPEN*, **2021**, 41, 293-298	1.3	2
125	Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis. *Molecular Genetics and Metabolism*, **2021**, 132, 119-127	3.7	2
124	Pathophysiology and management of classic galactosemic primary ovarian insufficiency.. *Reproduction and Fertility*, **2021**, 2, R67-R84	1.1	0
123	Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene. *Human Mutation*, **2021**, 42, 1624-1636	4.7	1
122	Creatine metabolism in patients with urea cycle disorders. *Molecular Genetics and Metabolism Reports*, **2021**, 29, 100791	1.8	2
121	Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. *Molecular Genetics and Metabolism*, **2021**, 132, 19-26	3.7	3
120	Retrospective analysis of 19 patients with 6-Pyruvoyl Tetrahydropterin Synthase Deficiency: Prolactin levels inversely correlate with growth. *Molecular Genetics and Metabolism*, **2020**, 131, 380-389	3.7	3

119	Laboratory evaluation of homocysteine remethylation disorders and classic homocystinuria: Long-term follow-up using a cohort of 123 patients. *Clinica Chimica Acta*, **2020**, 509, 126-134	6.2	2
118	Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. *Molecular Genetics and Metabolism*, **2020**, 130, 239-246	3.7	9
117	Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency. *Molecular Genetics and Metabolism*, **2020**, 129, 13-19	3.7	12
116	Histone H3.3 beyond cancer: Germline mutations in cause a previously unidentified neurodegenerative disorder in 46 patients. *Science Advances*, **2020**, 6,	14.3	12
115	Parkes Weber syndrome associated with two somatic pathogenic variants in. *Journal of Physical Education and Sports Management*, **2020**, 6,	2.8	6
114	Exploratory study of the effect of one week of orally administered CNSA-001 (sepiapterin) on CNS levels of tetrahydrobiopterin, dihydrobiopterin and monoamine neurotransmitter metabolites in healthy volunteers. *Molecular Genetics and Metabolism Reports*, **2019**, 21, 100500	1.8	3
113	A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patientsS preferences. *Molecular Genetics and Metabolism Reports*, **2019**, 21, 100507	1.8	3
112	Clinical and biochemical outcome of patients with very long-chain acyl-CoA dehydrogenase deficiency. *Molecular Genetics and Metabolism*, **2019**, 127, 64-73	3.7	15
111	Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. *Molecular Genetics and Metabolism*, **2019**, 126, 406-412	3.7	12
110	Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients. *Molecular Genetics and Metabolism*, **2019**, 127, 336-345	3.7	5
109	Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. *Molecular Genetics and Metabolism*, **2019**, 128, 84-91	3.7	9
108	SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals. *Human Mutation*, **2019**, 40, 908-925	4.7	23
107	Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts. *Pharmacology Research and Perspectives*, **2019**, 7, e00525	3.1	4
106	Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. *Genetics in Medicine*, **2019**, 21, 1851-1867	8.1	29
105	Acute Presentation and Management of the Encephalopathic Child With an Undiagnosed Inborn Error of Metabolism. *Journal of Emergency Medicine*, **2019**, 56, e5-e8	1.5	2
104	Extrapolation of Variant Phase in Mitochondrial Short-Chain Enoyl-CoA Hydratase (ECHS1) Deficiency. *JIMD Reports*, **2019**, 43, 103-109	1.9	9
103	Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial. *Molecular Genetics and Metabolism*, **2018**, 123, 347-356	3.7	11
102	Biochemical changes and clinical outcomes in 34 patients with classic galactosemia. *Journal of Inherited Metabolic Disease*, **2018**, 41, 197-208	5.4	15

101	Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. *Molecular Genetics and Metabolism*, **2018**, 124, 20-26	3.7	32
100	Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. *Orphanet Journal of Rare Diseases*, **2018**, 13, 108	4.2	17
99	Effect of genotype on galactose-1-phosphate in classic galactosemia patients. *Molecular Genetics and Metabolism*, **2018**, 125, 258-265	3.7	3
98	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. *Molecular Genetics and Metabolism*, **2018**, 125, 217-227	3.7	14
97	Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories. *Orphanet Journal of Rare Diseases*, **2018**, 13, 219	4.2	20
96	Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders. *Molecular Genetics and Metabolism*, **2018**, 125, 251-257	3.7	4
95	Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics. *Genetics in Medicine*, **2017**, 19, 256-263	8.1	13
94	Functional and molecular studies in primary carnitine deficiency. *Human Mutation*, **2017**, 38, 1684-1699	4.7	34
93	Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. *Molecular Genetics and Metabolism*, **2017**, 122, 46-53	3.7	11
92	Global Analysis of Plasma Lipids Identifies Liver-Derived Acylcarnitines as a Fuel Source for Brown Fat Thermogenesis. *Cell Metabolism*, **2017**, 26, 509-522.e6	24.6	105
91	Anaplerotic therapy in propionic acidemia. *Molecular Genetics and Metabolism*, **2017**, 122, 51-59	3.7	18
90	Glycerol phenylbutyrate for the maintenance treatment of patients with deficiencies in enzymes of the urea cycle. *Expert Opinion on Orphan Drugs*, **2017**, 5, 999-1010	1.1	8
89	Neonatal Screening for Primary Carnitine Deficiency: Lessons Learned from the Faroe Islands. *International Journal of Neonatal Screening*, **2017**, 3, 1	2.6	10
88	Diagnosis, Treatment, and Clinical Outcome of Patients with Mitochondrial Trifunctional Protein/Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency. *JIMD Reports*, **2017**, 31, 63-71	1.9	17
87	Round Table Discussion. *Annals of Nutrition and Metabolism*, **2016**, 68 Suppl 3, 21-23	4.5	
86	Effect of dietary lysine restriction and arginine supplementation in two patients with pyridoxine-dependent epilepsy. *Molecular Genetics and Metabolism*, **2016**, 118, 167-172	3.7	21
85	Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase. *Molecular Genetics and Metabolism*, **2016**, 117, 164-71	3.7	16
84	A novel method for simultaneous quantification of alpha-aminoadipic semialdehyde/piperideine-6-carboxylate and pipecolic acid in plasma and urine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2016**, 1017-1018, 145-152	3.2	13

83	Wide tolerance to amino acids substitutions in the OCTN1 ergothioneine transporter. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 1334-42	4	5
82	Carnitine transport and fatty acid oxidation. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 2422-35	4.9	315
81	Creatine Transporter Deficiency: Screening of Males with Neurodevelopmental Disorders and Neurocognitive Characterization of a Case. *Journal of Developmental and Behavioral Pediatrics*, **2016**, 37, 322-6	2.4	7
80	Primary Carnitine Deficiency and Newborn Screening for Disorders of the Carnitine Cycle. *Annals of Nutrition and Metabolism*, **2016**, 68 Suppl 3, 5-9	4.5	38
79	Cytotoxic edema and diffusion restriction as an early pathoradiologic marker in canavan disease: case report and review of the literature. *Orphanet Journal of Rare Diseases*, **2016**, 11, 169	4.2	8
78	Creatine transporter deficiency: Novel mutations and functional studies. *Molecular Genetics and Metabolism Reports*, **2016**, 8, 20-3	1.8	12
77	Loss-of-Function Mutations in ELMO2 Cause Intraosseous Vascular Malformation by Impeding RAC1 Signaling. *American Journal of Human Genetics*, **2016**, 99, 299-317	11	15
76	Biochemical abnormalities in Pearson syndrome. *American Journal of Medical Genetics, Part A*, **2015**, 167A, 621-8	2.5	26
75	Long-term safety and efficacy of sapropterin: the PKUDOS registry experience. *Molecular Genetics and Metabolism*, **2015**, 114, 557-63	3.7	32
74	Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. *Molecular Genetics and Metabolism*, **2015**, 116, 29-34	3.7	8
73	Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. *Genetics in Medicine*, **2015**, 17, 561-8	8.1	23
72	Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia. *Nature Communications*, **2015**, 6, 8329	17.4	166
71	Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy. *Genetics in Medicine*, **2015**, 17, 365-73	8.1	14
70	Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. *Lancet, The*, **2014**, 384, 37-44	40	109
69	Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. *Molecular Genetics and Metabolism*, **2014**, 111, 16-25	3.7	77
68	National Institutes of Health (NIH) review of evidence in phenylalanine hydroxylase deficiency (phenylketonuria) and recommendations/guidelines for therapy from the American College of Medical Genetics (ACMG) and Genetics Metabolic Dietitians International (GMDI). *Molecular Genetics and Metabolism*, **2014**, 112, 85-6	3.7	7
67	Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. *Journal of Inherited Metabolic Disease*, **2014**, 37, 231-6	5.4	32
66	The effect of valinomycin in fibroblasts from patients with fatty acid oxidation disorders. *Biochemical and Biophysical Research Communications*, **2013**, 437, 637-41	3.4	5

65	Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency. *Molecular Genetics and Metabolism*, **2013**, 110, 255-62	3.7	20
64	Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology*, **2013**, 57, 2171-9	11.2	61
63	Response to chen et Al.: carnitine uptake defect (primary carnitine deficiency): risk in genotype-phenotype correlation. *Human Mutation*, **2013**, 34, 656	4.7	3
62	Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. *American Journal of Hematology*, **2013**, 88, 172-8	7.1	43
61	Metabolic Lysosomal Enzyme Probes. *FASEB Journal*, **2013**, 27, 576.1	0.9	
60	Genotype-phenotype correlation in primary carnitine deficiency. *Human Mutation*, **2012**, 33, 118-23	4.7	45
59	Glutaric acidemia type 1: outcomes before and after expanded newborn screening. *Molecular Genetics and Metabolism*, **2012**, 106, 430-8	3.7	49
58	Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism. *Nature Genetics*, **2012**, 44, 1152-5	36.3	157
57	Newborn Screening for Metabolic Disorders **2012**, 163-197		
56	Primary Carnitine Deficiency Presents Atypically with Long QT Syndrome: A Case Report. *JIMD Reports*, **2012**, 2, 87-90	1.9	21
55	Newborn Screening and Inborn Errors of Metabolism **2012**, 2045-2082		1
54	Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 312-20	6.9	38
53	Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. *Journal of Inherited Metabolic Disease*, **2011**, 34, 963-71	5.4	29
52	Newborn screening and inborn errors of metabolism. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2011**, 157C, 1-2	3.1	4
51	Disorders of creatine transport and metabolism. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2011**, 157C, 72-8	3.1	71
50	Creatine transporter deficiency in two half-brothers. *American Journal of Medical Genetics, Part A*, **2010**, 152A, 1979-83	2.5	22
49	Recurrent liver failure in a 25-year-old female. *Liver Transplantation*, **2010**, 16, 1049-53	4.5	15
48	Developing a National Registry for conditions identifiable through newborn screening. *Genetics in Medicine*, **2009**, 11, 176-82	8.1	10

47	Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. *Journal of Pediatrics*, **2009**, 154, 700-7	3.6	142
46	Disorders of biopterin metabolism. *Journal of Inherited Metabolic Disease*, **2009**, 32, 333-42	5.4	99
45	A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. *Molecular Genetics and Metabolism*, **2009**, 96, 85-90	3.7	126
44	Cardiomyopathy and carnitine deficiency. *Molecular Genetics and Metabolism*, **2008**, 94, 162-6	3.7	53
43	Progressive cerebral vascular degeneration with mitochondrial encephalopathy. *American Journal of Medical Genetics, Part A*, **2008**, 146A, 361-7	2.5	25
42	Expanded newborn screening identifies maternal primary carnitine deficiency. *Molecular Genetics and Metabolism*, **2007**, 90, 441-5	3.7	74
41	Pharmacological rescue of carnitine transport in primary carnitine deficiency. *Human Mutation*, **2006**, 27, 513-23	4.7	35
40	Inborn errors of metabolism: new challenges with expanded newborn screening programs. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2006**, 142C, 61-3	3.1	2
39	Biochemical findings in common inborn errors of metabolism. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2006**, 142C, 64-76	3.1	31
38	Disorders of carnitine transport and the carnitine cycle. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2006**, 142C, 77-85	3.1	320
37	Glutaric acidemia type 1. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2006**, 142C, 86-94	3.1	71
36	Metabolic changes associated with hyperammonemia in patients with propionic acidemia. *Molecular Genetics and Metabolism*, **2006**, 88, 123-30	3.7	66
35	Homozygous nonsense mutation in the MCEE gene and siRNA suppression of methylmalonyl-CoA epimerase expression: a novel cause of mild methylmalonic aciduria. *Molecular Genetics and Metabolism*, **2006**, 88, 327-33	3.7	28
34	Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene. *Human Mutation*, **2005**, 25, 306-13	4.7	51
33	Tyrosine residues affecting sodium stimulation of carnitine transport in the OCTN2 carnitine/organic cation transporter. *Journal of Biological Chemistry*, **2004**, 279, 7247-53	5.4	20
32	Succinyl-CoA:3-ketoacid transferase (SCOT) deficiency in a new patient homozygous for an R217X mutation. *Journal of Inherited Metabolic Disease*, **2004**, 27, 691-2	5.4	23
31	Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. *American Journal of Medical Genetics Part A*, **2004**, 126A, 150-5		32
30	Paternal uniparental disomy of chromosome 14: confirmation of a clinically-recognizable phenotype. *American Journal of Medical Genetics Part A*, **2004**, 130A, 88-91		22

29	A primer on newborn screening. *Advances in Neonatal Care*, **2004**, 4, 306-17	2	9
28	6q subtelomeric deletion: is there a recognizable syndrome?. *Clinical Dysmorphology*, **2004**, 13, 103-106	0.9	23
27	Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency. *Journal of Biological Chemistry*, **2003**, 278, 47776-84	5.4	23
26	Mitochondrial encephalopathy. *Neurologic Clinics*, **2003**, 21, 817-31	4.5	30
25	Gene expression in human cells with mutant insulin receptors. *Biochemical and Biophysical Research Communications*, **2003**, 307, 1013-20	3.4	6
24	The OCTN2 carnitine transporter and fatty acid oxidation **2003**, 161-174		
23	Genotype-phenotype correlation in inherited severe insulin resistance. *Human Molecular Genetics*, **2002**, 11, 1465-75	5.6	104
22	Insulin increases the turnover rate of Na+-K+-ATPase in human fibroblasts. *American Journal of Physiology - Cell Physiology*, **2001**, 280, C912-9	5.4	8
21	Phenotype and genotype variation in primary carnitine deficiency. *Genetics in Medicine*, **2001**, 3, 387-92	8.1	62
20	Insulin-induced gene 33 mRNA expression in Chinese hamster ovary cells is insulin receptor dependent **2000**, 77, 432-444		6
19	A missense mutation in the OCTN2 gene associated with residual carnitine transport activity. *Human Mutation*, **2000**, 15, 238-45	4.7	49
18	Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. *Human Mutation*, **2000**, 16, 401-7	4.7	61
17	Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency. *Journal of Biological Chemistry*, **2000**, 275, 20782-6	5.4	36
16	Primary and secondary alterations of neonatal carnitine metabolism. *Seminars in Perinatology*, **1999** , 23, 152-61	3.3	69
15	Progressive decline in insulin levels in Rabson-Mendenhall syndrome. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2623-9	5.6	45
14	Functional characterization of the carnitine transporter defective in primary carnitine deficiency. *Archives of Biochemistry and Biophysics*, **1999**, 364, 99-106	4.1	29
13	Role of arginine 86 of the insulin receptor in insulin binding and activation of glucose transport. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1998**, 1402, 86-94	4.9	4
12	Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency. *Genetics in Medicine*, **1998**, 1, 34-9	8.1	52

11	P-14: Mutational analysis of the insulin receptor: Arginine 86 plays an essential role in insulin binding and stimulation of glucose transport. *Experimental and Clinical Endocrinology and Diabetes*, **1996**, 104, 78-80	2.3	
10	Insulin stimulates the Na+,K(+)-ATPase and the Na+/K+/Cl- cotransporter of human fibroblasts. *Biochimica Et Biophysica Acta - Biomembranes*, **1996**, 1281, 38-44	3.8	15
9	Prenatal analysis of the insulin receptor gene in a family with leprechaunism. *Prenatal Diagnosis*, **1995**, 15, 1070-4	3.2	6
8	Glucose transport by cultured human fibroblasts: regulation by phorbol esters and insulin. *Biochimica Et Biophysica Acta - Biomembranes*, **1992**, 1104, 24-30	3.8	14
7	Insulin-receptor autophosphorylation and kinase activity are constitutively increased in fibroblasts cultured from a patient with heritable insulin-resistance. *Biochemical and Biophysical Research Communications*, **1990**, 167, 1229-34	3.4	8
6	Increased glucose transport by human fibroblasts with a heritable defect in insulin binding. *Metabolism: Clinical and Experimental*, **1989**, 38, 690-7	12.7	27
5	Restriction fragment length polymorphisms of the insulin receptor gene in families with insulin resistance and leprechaunism. *American Journal of the Medical Sciences*, **1989**, 298, 366-70	2.2	2
4	Glycine transport by cultured human fibroblasts. *Biochemical and Biophysical Research Communications*, **1988**, 152, 617-22	3.4	
3	Effect of extracellular potassium on amino acid transport and membrane potential in fetal human fibroblasts. *Biochimica Et Biophysica Acta - Biomembranes*, **1986**, 854, 240-50	3.8	26
2	Perturbation of Na+ and K+ gradients in human fibroblasts incubated in unsupplemented saline solutions. *Biochimica Et Biophysica Acta - Biomembranes*, **1986**, 860, 1-8	3.8	12
1	Effect of insulin on the activity of amino acid transport systems in cultured human fibroblasts. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1985**, 844, 216-23	4.9	26